Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODXNYSE:CSUNASDAQ:PTITSE:TRL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.29+2.9%$0.30$0.23▼$2.23$9.60M0.6248,668 shs86,170 shsCSUCapital Senior Living$31.66$8.62▼$58.94$73.49M2.1532,471 shs77 shsPTIProteostasis Therapeutics$11.24$0.87▼$2.72$37.57M1.161.04 million shs9,405 shsTRLTrilogy International PartnersC$0.00C$0.12▼C$2.50C$21.27MN/A68,686 shs239,293 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-0.79%+4.71%+6.11%-22.35%-77.94%CSUCapital Senior Living0.00%0.00%0.00%0.00%0.00%PTIProteostasis Therapeutics0.00%0.00%0.00%0.00%+30.20%TRLTrilogy International Partners0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCODXCo-Diagnostics4.5082 of 5 stars3.55.00.04.42.20.01.3CSUCapital Senior LivingN/AN/AN/AN/AN/AN/AN/AN/APTIProteostasis TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRLTrilogy International PartnersN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 3.00Buy$5.501,823.08% UpsideCSUCapital Senior Living 0.00N/AN/AN/APTIProteostasis Therapeutics 0.00N/AN/AN/ATRLTrilogy International Partners 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CSU, PTI, CODX, and TRL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$3.91M2.46N/AN/A$1.70 per share0.17CSUCapital Senior Living$383.86M0.00N/AN/A($131.19) per share0.00PTIProteostasis Therapeutics$5M0.00N/AN/A$1.22 per share0.00TRLTrilogy International PartnersC$407.64M0.00N/A0.77C$0.38 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$37.64M-$1.17N/AN/AN/A-1,025.45%-60.16%-52.69%8/6/2025 (Estimated)CSUCapital Senior Living-$295.37M$49.780.67N/AN/A40.40%N/A-5.64%N/APTIProteostasis Therapeutics-$59.13M-$1.16N/AN/AN/AN/A-75.39%-55.04%N/ATRLTrilogy International PartnersN/AC$6.340.04N/A0.86N/AN/AN/AN/ALatest CSU, PTI, CODX, and TRL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/ACSUCapital Senior LivingN/AN/AN/AN/AN/APTIProteostasis TherapeuticsN/AN/AN/AN/AN/ATRLTrilogy International PartnersC$1.31704.17%N/A20.69%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A4.434.23CSUCapital Senior LivingN/A0.110.11PTIProteostasis TherapeuticsN/A6.696.69TRLTrilogy International PartnersN/A5.923.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%CSUCapital Senior Living62.65%PTIProteostasis Therapeutics16.64%TRLTrilogy International PartnersN/AInsider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics6.10%CSUCapital Senior Living5.46%PTIProteostasis Therapeutics4.80%TRLTrilogy International PartnersN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics10033.57 million31.53 millionOptionableCSUCapital Senior Living3,4162.19 million2.07 millionOptionablePTIProteostasis Therapeutics4452.19 millionN/ANot OptionableTRLTrilogy International Partners70,00088.63 millionN/ANot OptionableCSU, PTI, CODX, and TRL HeadlinesRecent News About These CompaniesGPS PEP Expands User Base in Deal With Investment Advisory TrilogySeptember 11, 2024 | planadviser.comPThe Lord of the Rings Trilogy Theatrical Rerelease Dates Set for 2024 ReturnApril 26, 2024 | yahoo.comPeloton Capital invests in financial planning and wealth advisor TrilogyMarch 12, 2024 | pehub.comSG Enterprises II submits non-binding offer to acquire Trilogy InternationalDecember 18, 2023 | msn.comSG Enterprises II, LLC Submits Non-Binding Offer To Acquire Trilogy International Partners Inc.December 18, 2023 | finance.yahoo.comTrilogy International Partners Inc TRL.HNovember 21, 2023 | morningstar.comMTrilogy International Partners Inc. Reports Third Quarter 2023 Results and Appoints DirectorNovember 13, 2023 | finance.yahoo.comTrilogy Intl Partners: Top 10 Undervalued Telecommunication Services Industry Stocks (TRL-H)September 15, 2023 | theglobeandmail.comTrilogy International Partners Inc. Announces Completion of Distribution to ShareholdersJuly 28, 2023 | finance.yahoo.comBatman Arkham Trilogy For Switch Only Includes One Title On The Game CartridgeJune 26, 2023 | nintendolife.comNCompanies with the highest dividend payout growth over the last 5 years.May 14, 2023 | msn.comTrilogy International Ltd (TIL)May 14, 2023 | investing.comTrilogy International Partners Inc. Reports First Quarter 2023 ResultsMay 11, 2023 | finance.yahoo.comTrilogy International Partners GAAP EPS of -$0.03April 1, 2023 | seekingalpha.comTrilogy International Partners Inc. Announces New Listing on the NEX Board of the TSX Venture Exchange and Concurrent Voluntary Delisting from the TSXDecember 9, 2022 | finance.yahoo.comRian Johnson Confirms What’s Holding Back His Star Wars TrilogyOctober 31, 2022 | denofgeek.comD‘Rings of Power’ Finale Reveals Biggest Nod Yet to ‘Lord of the Rings’ Film TrilogyOctober 16, 2022 | indiewire.comIHilary Mantel, Double Booker Prize Winner and Author of Wolf Hall Trilogy, Dies SuddenlyOctober 1, 2022 | thedailybeast.comTNew On Peacock In October 2022: Halloween Ends, Back To The Future Trilogy, And Galaxy QuestSeptember 28, 2022 | gamespot.comGStar Wars leak: Luke Skywalker 'to get new trilogy' set before Force AwakensSeptember 28, 2022 | express.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismSilver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyAT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?By Jeffrey Neal Johnson | June 5, 2025View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?Reddit Stock Ignites: Surge in Call Options Signals Big BetBy Gabriel Osorio-Mazilli | June 24, 2025View Reddit Stock Ignites: Surge in Call Options Signals Big BetCSU, PTI, CODX, and TRL Company DescriptionsCo-Diagnostics NASDAQ:CODX$0.29 +0.01 (+2.88%) Closing price 04:00 PM EasternExtended Trading$0.28 0.00 (-1.75%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Capital Senior Living NYSE:CSUCapital Senior Living Corp. engages in the operation of senior housing communities. Its senior living options include independent living, assisted living, and memory care. The company was founded in 1990 and is headquartered in Dallas, TX.Proteostasis Therapeutics NASDAQ:PTIProteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.Trilogy International Partners TSE:TRLTrilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services in New Zealand, Bolivia, and internationally. It offers prepaid and postpaid payment plans, including local, international long distance, and roaming services to customers and international visitors roaming on its networks. The company also provides fixed broadband communications to residential and enterprise customers, as well as a range of mobile and fixed line services in New Zealand and Australia; and fixed public telephony and wireless broadband services in Bolivia. As of December 31, 2021, it had a distribution network of approximately 13 company owned stores, 170 dealers, and 8,300 other dealer points of presence in Bolivia; and a distribution network of approximately 20 company owned retail stores, 40 independent dealers, and 2,500 points of sale through national retail chains and grocery stores in New Zealand. The company's services cover an aggregate population of 16.8 million users. It also provides services through its online self-service store in New Zealand; and operates under the Viva brand name in Bolivia. Trilogy International Partners Inc. was founded in 1982 and is headquartered in Bellevue, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
